Prelude Therapeutics to Present at American Association for Cancer Research 2023 Conference

Rhea-AI Summary

Prelude Therapeutics (Nasdaq: PRLD), a clinical-stage precision oncology company, announced the presentation of eight abstracts at the American Association for Cancer Research (AACR) Annual Meeting 2023, occurring from April 14-19 in Orlando, Florida. The research highlights progress in their pipeline, including two clinical abstracts on compounds PRT1419 and PRT2527, which target specific cancer pathways in advanced tumors. Jane Huang, President and CMO, noted the supportive safety and pharmacokinetic profiles for further development in hematological cancers. Additionally, preclinical data on the SMARCA2 degrader program will be presented, alongside favorable data on other candidates such as PRT3645 and PRT3789. This showcases Prelude's commitment to innovative treatment options for cancer patients.

Eight Abstracts Demonstrate Progress of Prelude’s Differentiated Pipeline

WILMINGTON, Del., April 11, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced details relating to eight abstracts being presented at the American Association for Cancer Research (AACR) Annual Meeting 2023, taking place April 14-19 in Orlando, Florida.

“Prelude's six preclinical and two clinical abstracts being presented at the AACR Annual Meeting highlight the important progress we are making across our pipeline. Initial safety, pharmacokinetic and pharmacodynamic profiles in solid tumors for both PRT2527 and PRT1419 support continued development of both compounds in hematological cancers,” said Jane Huang, M.D., President and Chief Medical Officer of Prelude. “Additionally, we will be presenting preclinical data on our orally bioavailable SMARCA2 degrader program for the first time.”  

“We are also presenting preclinical data for both our next generation CDK4/6 inhibitor, PRT3645, and our SMARCA2 degrader, PRT3789, in combination with other targeted therapies. These studies demonstrate the favorable combinability of our compounds with standard of care medicines and inform potential clinical development,” added Peggy Scherle, Ph.D., Chief Scientific Officer of Prelude.

Details of the clinical abstracts upcoming presentations are as follows: 

Title: A phase 1, open-label, dose-escalation study of PRT1419, a selective induced myeloid leukemia cell differentiation protein (MCL-1) inhibitor, in patients (pts) with advanced/metastatic solid tumors
Presenter: Gerald Falchook 
Session Title: First-in-Human Phase I Clinical Trials 2 
Date and Time: Tuesday April 18, 2023, 9:00 AM - 12:30 PM 
Location: Poster Section 45 
Poster Board Number: 4 
Abstract Presentation Number: CT172 

Title: A phase 1, open-label, multicenter, dose-escalation study of PRT2527, a cyclin-dependent kinase 9 (CDK9) inhibitor, in adult patients (pts) with advanced solid tumors
Presenter: Jason T. Henry 
Session Title: First-in-Human Phase I Clinical Trials 2 
Date and Time: Tuesday April 18, 2023 9:00 AM - 12:30 PM 
Location: Poster Section 45 
Poster Board Number: 5 
Abstract Presentation Number: CT173  

Details of the preclinical abstracts are as follows: 

Title: SMARCA2 (BRM) degraders promote differentiation and inhibit proliferation in AML models 
Presenter: Anjana Agarwal 
Session Category: Experimental and Molecular Therapeutics 
Session Title: New Therapeutic Targeted Agents 
Date and Time: Monday April 17, 2023 9:00 AM - 12:30 PM 
Location: Section 16 
Poster Board Number: 17 
Abstract Presentation Number: 1594 

Title: Development of pharmacodynamic assays for quantifying SMARCA2 protein degradation and target gene expression in response to a SMARCA2 degrader (PRT3789) 
Presenter: Andrew Moore 
Session Category: Experimental and Molecular Therapeutics 
Session Title: Pharmacokinetics, Pharmacodynamics, and Molecular Pharmacology 
Date and Time: Monday April 17, 2023 1:30 PM - 5:00 PM 
Location: Section 18 
Poster Board Number: 15 
Abstract Presentation Number: 2792 

Title: Combination therapy with selective SMARCA2 (BRM) degraders for treatment of SMARCA4 (BRG1)-deficient cancers 
Presenter: Michael Hulse 
Session Category: Experimental and Molecular Therapeutics 
Session Title: Epigenetics 
Date and Time: Wednesday April 19, 2023 9:00 AM - 12:30 PM 
Location: Section 20 
Poster Board Number: 8 
Abstract Presentation Number: 6270 

Title: The brain penetrant CDK4/6 Inhibitor, PRT3645, is highly effective in combination with other targeted therapies in preclinical models of NSCLC and HER2-positive breast cancer 
Presenter: Yue Zou 
Session Category: Molecular/Cellular Biology and Genetics 
Session Title: Cyclin-dependent Kinases and Cyclin-dependent Kinase Inhibitors 
Date and Time: Wednesday April 19, 2023 9:00 AM - 12:30 PM 
Location: Section 9 
Poster Board Number: 2 
Abstract Presentation Number: 5973  

Title: MCL1 inhibitor PRT1419 demonstrates anti-tumor activity in PBRM1-altered clear cell renal cancer and synergizes with standard of care agents 
Presenter: Norman Fultang 
Session Category: Experimental and Molecular Therapeutics 
Session Title: Cell Death Pathways and Treatment / Molecular Classification of Tumors for Diagnostics, Prognostics, and Therapeutic Outcomes 
Date and Time: Wednesday April 19, 2023 9:00 AM - 12:30 PM 
Location: Section 16 
Poster Board Number: 9 
Abstract Presentation Number: 6147 

Title: Selective and orally bioavailable SMARCA2 targeted degraders induce synthetic lethality in SMARCA4- deficient solid tumor 
Presenter: Koichi Ito 
Session Category: Experimental and Molecular Therapeutics 
Session Title: Epigenetics 
Date and Time: Wednesday April 19, 2023 9:00 AM - 12:30 PM 
Location: Section 20 
Poster Board Number: 15 
Abstract Presentation Number: 6277 

About Prelude Therapeutics 

Prelude Therapeutics is a clinical-stage precision oncology company developing innovative drug candidates targeting critical cancer cell pathways. The Company’s diverse pipeline is comprised of highly differentiated, potentially best-in-class or first-in-class proprietary small molecule compounds aimed at addressing clinically validated pathways for cancers with selectable underserved patients. Prelude’s pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1, PRT2527, a potent and highly selective CDK9 inhibitor, PRT3645, a next generation CDK4/6 inhibitor, and PRT3789, an IV administered, potent and highly selective SMARCA2 degrader.

For more information, visit our website and follow us on LinkedIn and Twitter.

Cautionary Note Regarding Forward-Looking Statements 

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, anticipated discovery, preclinical and clinical development activities, timing of availability and announcements of clinical results for Prelude’s product candidates, and the potential benefits of Prelude’s product candidates . All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Although Prelude believes that the expectations reflected in such forward-looking statements are reasonable, Prelude cannot guarantee future events, results, actions, levels of activity, performance or achievements, and the timing and results of biotechnology development and potential regulatory approval is inherently uncertain. Forward-looking statements are subject to risks and uncertainties that may cause Prelude's actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to Prelude's ability to advance its product candidates, the receipt and timing of potential regulatory designations, approvals and commercialization of product candidates, the impact of the COVID-19 pandemic on Prelude’s business, clinical trial sites, supply chain and manufacturing facilities, Prelude’s ability to maintain and recognize the benefits of certain designations received by product candidates, the timing and results of preclinical and clinical trials, Prelude's ability to fund development activities and achieve development goals, Prelude's ability to protect intellectual property, and other risks and uncertainties described under the heading "Risk Factors" in documents Prelude files from time to time with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and Prelude undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof. 

Investor Contact: 
Lindsey Trickett 
Vice President, Investor Relations 
240.543.7970 
ltrickett@preludetx.com  

Media Contact: 
Helen Shik  
Shik Communications  
617.510.4373  
Helen@ShikCommunications.com 

FAQ

What is the significance of the eight abstracts presented by Prelude Therapeutics at AACR 2023?

The eight abstracts showcase Prelude's advancements in cancer treatment, particularly highlighting safety and efficacy data for their drugs PRT1419 and PRT2527.

When is Prelude Therapeutics presenting its clinical abstracts at AACR 2023?

Prelude is presenting its clinical abstracts on April 18, 2023, during a session from 9:00 AM to 12:30 PM.

What compounds are being highlighted in the AACR 2023 presentations by Prelude Therapeutics?

The highlighted compounds include PRT1419, a MCL1 inhibitor, and PRT2527, a CDK9 inhibitor, along with preclinical data on PRT3645 and PRT3789.

What are the targeted cancer pathways for Prelude's drug candidates?

Prelude's drug candidates target critical pathways in cancer cells, focusing on MCL1, CDK9, and SMARCA2 for treating advanced solid tumors.

What is the focus of the preclinical data being presented by Prelude at AACR 2023?

The preclinical data focus on the new SMARCA2 degrader program and its effectiveness in combination with other cancer therapies.